ResearcherFred and Pamela Buffett Cancer CenterNo recent work listed

Staci L. Haney

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-7826-6090; OpenAlex author ID A5111932934. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2019: 1 paper

Papers 1

Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-019-0794-6 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kamiya Mehla · 1 shared paper, 2019 · strength 0.09
- Paper Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-019-0794-6 ↗
Lynette M. Smith · 1 shared paper, 2019 · strength 0.09
- Paper Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-019-0794-6 ↗
Daryl J. Murry · 1 shared paper, 2019 · strength 0.09
- Paper Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-019-0794-6 ↗
Sarah A Holstein · 1 shared paper, 2019 · strength 0.09
- Paper Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-019-0794-6 ↗
Michael Anthony Hollingsworth · 1 shared paper, 2019 · strength 0.09
- Paper Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-019-0794-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.